|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
Founded in 2019, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (TA-8995), a novel, selective, cholesteryl ester transfer protein (CETP) inhibitor. The Company is investigating Obicetrapib as the preferred LDL-c lowering therapy for patients who cannot be treated optimally with current available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally tolerated statin therapy.
In January 2021, NewAmsterdam completed its Series A funding round of $196M (€160M) which will support the full Phase 3 development of Obicetrapib.
|
NewAmsterdam Pharma Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used NewAmsterdam Pharma email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact NewAmsterdam Pharma customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.